Metabolic dysfunction–associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease worldwide and a major contributor to cardiometabolic morbidity. Notably, cardiovascular disease, rather than liver-related complications, is the leading cause of mortality among individuals with MASLD, highlighting the importance of accurate cardiovascular risk stratification in this population.1,2 Obesity represents a core component of the MASLD diagnostic framework;1,3,4 however, its definition has recently undergone substantial revision.
Metabolic dysfunction–associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease worldwide and a major contributor to cardiometabolic morbidity. Notably, cardiovascular disease, rather than liver-related complications, is the leading cause of mortality among individuals with MASLD, highlighting the importance of accurate cardiovascular risk stratification in this population.1,2 Obesity represents a core component of the MASLD diagnostic framework;1,3,4 however, its definition has recently undergone substantial revision.